• Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%
  • Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%
  • Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%
  • Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%
  • Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%

Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%

Certification: ISO
Assay Method: UV
Application Form: Powder
Application: Health Care Products
State: Powder
Extract Source: PRO-Xylane
Samples:
US$ 20/10G 1 10G(Min.Order)
| Request Sample
Customization:
Diamond Member Since 2023

Suppliers with verified business licenses

Rating: 5.0/5
Shaanxi, China
Importers and Exporters
The supplier has import and export rights
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
to see all verified strength labels (9)

Basic Info.

Model NO.
powder
Transport Package
1kg/Bag, 25kg/Drum
Specification
99%
Origin
China
HS Code
2938909020
Production Capacity
100kg/Month

Product Description

Product Name: Levodopa
CAS:59-92-7
Molecular formula:C9H11NO4
Molecular weight:197.190
Melting point:276 - 278 ºC
Boiling point:448.4 ºC
Flash point:225 ºC
Product specifications:99%
Detection method:HPLC/UV
Physical properties: white powder
Solubility:Easy to dissolve in  water 
 
Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%
Levodopa Effect:

1. Parkinson's disease (primary tremor paralysis)
Symptomatic Parkinson's syndrome after encephalitis or in combination with cerebral arteriosclerosis and carbon monoxide and manganese poisoning of the central nervous system (non-pharmacological tremor paralysis syndrome). It can reduce the symptoms of tremor paralysis, improve muscle tone and normalize limb movement. The effect is better for those with mild and moderate conditions, and worse for severe or elderly patients.
2,Hepatic encephalopathy
It can make the patient awake and improve the symptoms. Hepatic encephalopathy may be related to the central transmitter dopamine abnormalities, after taking, can improve the central function and work. It is also believed that levodopa can improve the brain's tolerance to ammonia, but cannot improve liver damage and liver function.
3,Neuralgia
Early administration can relieve neuralgia.
4,Hyperprolactinemia
It can inhibit thyrotropin-releasing hormone of hypothalamus and excite prolactin-releasing inhibitory factor, thus reducing the secretion of prolactin, which is used for the treatment of hyperprolactinemia, and it has certain curative effect on lactoblastosis.
5,Dehydration
The mechanism may be to increase the concentration of catecholamines from blood to tissues to promote hair growth.
6. Promoting pediatric growth and development
It can accelerate the growth and development of pediatric bones by promoting the secretion. Treatment of children with hypopituitarism.

Levodopa  Adverse Reactions:

Adverse reactions are more frequent and difficult to avoid due to the long duration of administration. They are mainly caused by excessive peripheral production of dopamine. Appropriate adjustment of the dose can reduce the adverse reactions.
1, gastrointestinal reactions: nausea, vomiting, loss of appetite, seen in the early stage of treatment, about 80% of patients. After 3 months of using the drug can appear uneasiness, insomnia, hallucinations, psychiatric symptoms, in addition to postural hypotension, cardiac arrhythmia and involuntary movement and so on. Attention should be paid to adjust the dose, if necessary, stop the drug.
2,"Switch "phenomenon(the patient's sudden hyperactivity and restlessness is "open", and then there is a myotonic movement can not be "off"), seen in younger patients, about one year after the drug. It is seen in younger patients and occurs in some patients more than one year after drug administration. This phenomenon can be reversed or controlled by dose reduction or intravenous levodopa.
Intraday fluctuations may be due to the narrower dopamine sensitivity threshold of striatal dopamine receptors. When the dopamine concentration peaks after taking this product, dyskinesia occurs; when the dopamine concentration decreases it reverses to an inactive state, producing significant fluctuations in motor symptoms within a day. Appropriate adjustment of the time and method of taking, small doses divided into several times, can reduce the fluctuation phenomenon within the day.
4. Difficulty in urination, which is more likely to occur in the elderly.
Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%

Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%Antiepileptic Mucuna Pruriens Extract CAS: 59-92-7 Levodopa L-Dopa Powder99%

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now